KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Capital Leases: 2012-2024

Historic Capital Leases for Novavax (NVAX) over the last 6 years, with Dec 2024 value amounting to $53.7 million.

  • Novavax's Capital Leases fell 95.83% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 95.83%. This contributed to the annual value of $53.7 million for FY2024, which is 3.93% down from last year.
  • Novavax's Capital Leases amounted to $53.7 million in FY2024, which was down 3.93% from $55.9 million recorded in FY2023.
  • Novavax's 5-year Capital Leases high stood at $55.9 million for FY2023, and its period low was $31.2 million during FY2022.
  • Its 3-year average for Capital Leases is $47.0 million, with a median of $53.7 million in 2024.
  • Per our database at Business Quant, Novavax's Capital Leases spiked by 79.02% in 2023 and then declined by 3.93% in 2024.
  • Novavax's Capital Leases (Yearly) stood at $40.1 million in 2020, then reached $31.2 million in 2022, then skyrocketed by 79.02% to $55.9 million in 2023, then decreased by 3.93% to $53.7 million in 2024.